A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix) in Treating Spinocerebellar Ataxia Type 3.

Trial Profile

A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix) in Treating Spinocerebellar Ataxia Type 3.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2012

At a glance

  • Drugs Varenicline (Primary)
  • Indications Machado-Joseph Disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jun 2012 Actual end date changed from Dec 2011 to Apr 2011 as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 15 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top